Study: Marijuana Provided For FDA-Approved Clinical Research Genetically Similar to Hemp

Generic 16 April 2019 | 0 Comments

Marijuana grown by the University of Mississippi for clinical research purposes is genetically divergent from strains of cannabis commercially available in retail markets, according to an analysis prepared by researchers at the University of Northern Colorado. Since 1968, the University of Mississippi farm, which is governed by the US National Institute on Drug Abuse, has […]

Tagged in , , ,

DEA Reaffirms Stance That CBD Meets Schedule I Criteria — Reality Says Otherwise

Generic 11 July 2017 | 0 Comments

The US Drug Enforcement Administration has publicly reiterated its position that cannabidiol, a non-psychotropic cannabinoid, is properly categorized under federal law as a schedule I controlled substance — meaning that, by definition, it possesses “a high potential for abuse,” “no currently accepted medical use in treatment in the United States,” and lacks “accepted safety … […]

Tagged in , , ,

It Is Time To Deschedule, Not Reschedule, Cannabis

Generic 7 April 2016 | 0 Comments

A recent memorandum from the US Drug Enforcement Administration to several United States Senators indicates that the agency is prepared to respond in the coming months to a five-year-old petition seeking to amend the plant’s status as a schedule I prohibited substance. Under the US Controlled Substances Act of 1970, the cannabis plant and its […]

Tagged in , , ,

Senators Press Feds for Answers Regarding the State of Medical Marijuana Research

Generic 16 July 2015 | 0 Comments

Massachusetts Senator Elizabeth Warren, along with seven other Senators, has directed a letter to the Obama administration demanding regulators answer questions specific to the facilitation of research into the medical benefits of marijuana. Senators acknowledged the need for unbiased research. They wrote, “While the federal government has emphasized research on the potential harms associated with the use of marijuana, there is still very limited research on […]

Tagged in , ,

NIDA Acknowledges Drawbacks to Monopoly on Marijuana Supply

Generic 26 June 2015 | 0 Comments

Members of the US Senate at a hearing yesterday expressed skepticism in regard to federal policies limiting the ability of investigators to engage in clinical studies of marijuana’s health benefits. Senators heard from representatives from the Drug Enforcement Administration (DEA), Food and Drug Administration (FDA), National Institute on Drug Abuse (NIDA), University of Mississippi Medical […]

Tagged in , , ,